Publications
Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
Researchers discucss asparagine reliance of sarcoma cells may represent a metabolic vulnerability with potential anti-sarcoma therapeutic value.
Researchers show that the androgen receptor cistrome undergoes extensive reprogramming during prostate epithelial transformation in man and establish the centrality of epigenetic reprogramming in human prostate tumorigenesis.
Investigators used ultra-pH-sensitive nanoparticles to study endosomes and lysosomes.
The combination of chemical carcinogens with genetically engineered mouse models has emerged as an invaluable approach to study the complex interaction between genotype and environment that contributes to cancer development.
The authors used network-based analysis of treatment signatures from GEM models to identify treatment-responsive genes in human prostate cancer that are potential biomarkers of patient response.
Researchers identify Hepatocyte growth factor dependent signature may serve as a candidate predictive signature for patient enrollment in clinical trials using MET inhibitors.
Researchers find that activation of EGFR signaling leads to resistance of BRAF inhibitors, and that adding EGFR inhibitors increases the efficacy of BRAF inhibitor treatment.
Researchers used a next-generation shRNA platform to screen for genes conferring resistance to carfilzomib in multiple myeloma cells.
Researcehrs describe the discovery of the small-molecule probe BRD5631, and demonstrate that BRD5631 affects several cellular disease phenotypes previously linked to autophagy.
Whole-genome sequencing showed high frequency of mutations that were predicted to activate the RAS-MAPK pathway in relapse neuroblastoma samples as well as in neuroblastoma cell lines.